IGM Biosciences Inc (IGMS)
8.34
-0.95
(-10.23%)
USD |
NASDAQ |
May 20, 16:00
8.34
0.00 (0.00%)
After-Hours: 16:18
IGM Biosciences Enterprise Value: 250.43M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 250.43M |
| May 16, 2024 | 254.56M |
| May 15, 2024 | 266.37M |
| May 14, 2024 | 249.25M |
| May 13, 2024 | 253.38M |
| May 10, 2024 | 257.51M |
| May 09, 2024 | 303.55M |
| May 08, 2024 | 257.51M |
| May 07, 2024 | 292.34M |
| May 06, 2024 | 298.24M |
| May 03, 2024 | 300.60M |
| May 02, 2024 | 262.82M |
| May 01, 2024 | 265.78M |
| April 30, 2024 | 273.95M |
| April 29, 2024 | 278.08M |
| April 26, 2024 | 260.39M |
| April 25, 2024 | 157.22M |
| April 24, 2024 | 175.50M |
| April 23, 2024 | 160.17M |
| April 22, 2024 | 104.17M |
| April 19, 2024 | 130.69M |
| April 18, 2024 | 143.07M |
| April 17, 2024 | 185.52M |
| April 16, 2024 | 248.60M |
| April 15, 2024 | 260.98M |
| Date | Value |
|---|---|
| April 12, 2024 | 246.22M |
| April 11, 2024 | 199.06M |
| April 10, 2024 | 188.45M |
| April 09, 2024 | 221.46M |
| April 08, 2024 | 222.64M |
| April 05, 2024 | 222.64M |
| April 04, 2024 | 230.31M |
| April 03, 2024 | 238.56M |
| April 02, 2024 | 245.04M |
| April 01, 2024 | 263.32M |
| March 31, 2024 | 275.11M |
| March 28, 2024 | 229.61M |
| March 27, 2024 | 207.27M |
| March 26, 2024 | 172.59M |
| March 25, 2024 | 174.35M |
| March 22, 2024 | 267.24M |
| March 21, 2024 | 263.71M |
| March 20, 2024 | 241.96M |
| March 19, 2024 | 245.49M |
| March 18, 2024 | 276.06M |
| March 15, 2024 | 287.81M |
| March 14, 2024 | 261.95M |
| March 13, 2024 | 247.25M |
| March 12, 2024 | 247.25M |
| March 11, 2024 | 276.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-156.95M
Minimum
Oct 31 2023
3.510B
Maximum
Feb 09 2021
956.15M
Average
563.73M
Median
Feb 17 2023
Enterprise Value Benchmarks
| Akoya Biosciences Inc | 154.64M |
| Xilio Therapeutics Inc | 8.100M |
| NovaBay Pharmaceuticals Inc | 5.156M |
| Palatin Technologies Inc | 22.26M |
| iBio Inc | 16.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.82M |
| Revenue (Quarterly) | 0.497M |
| Total Expenses (Quarterly) | 54.35M |
| EPS Diluted (Quarterly) | -0.83 |
| Profit Margin (Quarterly) | -10.02K% |
| Earnings Yield | -51.32% |
| Normalized Earnings Yield | -51.32 |